Immune Check-Point Blockade as a Potential Therapeutic Strategy for Undifferentiated Malignancies

被引：0

作者：

Devereaux, Kelly ^{[1
]}

Charville, Gregory ^{[1
]}

Zhao, Shuchun ^{[1
]}

Cherry, Athena ^{[1
]}

van de Rijn, Matt ^{[1
]}

Natkunam, Yasodha ^{[1
]}

机构：

[1] Stanford Hlth Care, Stanford, CA USA

来源：

LABORATORY INVESTIGATION | 2017年 / 97卷

关键词：

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

1832

引用

页码：456A / 456A

页数：1

共 50 条

[41] Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade [J].

Jun Zhou ;

Jingjing Li ;

Indira Guleria ;

Tianqi Chen ;

Anita Giobbie-Hurder ;

Jonathan Stevens ;

Meghna Gupta ;

Xinqi Wu ;

Ryan C. Brennick ;

Michael P. Manos ;

F. Stephen Hodi .

Cancer Immunology, Immunotherapy, 2019, 68 :1331-1340

[42] Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade [J].

Zhou, Jun ;

Li, Jingjing ;

Guleria, Indira ;

Chen, Tianqi ;

Giobbie-Hurder, Anita ;

Stevens, Jonathan ;

Gupta, Meghna ;

Wu, Xinqi ;

Brennick, Ryan C. ;

Manos, Michael P. ;

Hodi, F. Stephen .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (08) :1331-1340

[43] Immunotherapy with check-point inhibitors (CPI) in adult malignancies: a protocol for the systematic review of the quality of economic analyses [J].

Ying Wang ;

Pierre Camateros ;

Denise Smith ;

David Dawe ;

Peter Ellis .

Systematic Reviews, 8

[44] Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond [J].

Lozar, Taja ;

Laklouk, Israa ;

Golfinos, Athena E. ;

Gavrielatou, Niki ;

Xu, Jin ;

Flynn, Christopher ;

Keske, Aysenur ;

Yu, Menggang ;

Bruce, Justine Y. ;

Wang, Wei ;

Kuhar, Cvetka Grasic ;

Bailey, Howard H. ;

Harari, Paul M. ;

Dinh, Huy Q. ;

Rimm, David L. ;

Hu, Rong ;

Lambert, Paul F. ;

Fitzpatrick, Megan B. .

CANCERS, 2023, 15 (19)

[45] Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer [J].

Fournel, Ludovic ;

Wu, Zherui ;

Stadler, Nicolas ;

Damotte, Diane ;

Lococo, Filippo ;

Boulle, Geoffroy ;

Segal-Bendirdjian, Evelyne ;

Bobbio, Antonio ;

Icard, Philippe ;

Tredaniel, Jean ;

Alifano, Marco ;

Forgez, Patricia .

CANCER LETTERS, 2019, 464 :5-14

[46] Proton pump inhibitors and response to immune check-point inhibitors: Single center study. [J].

Trabolsi, Asaad ;

Winter, Megan ;

Rodriquez, Estelamari .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[47] Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC) [J].

Sherman, Shira ;

Rotem, Ofer ;

Shochat, Tzippy ;

Zer, Alona ;

Moore, Assaf ;

Dudnik, Elizabeth .

LUNG CANCER, 2020, 143 :40-46

[48] Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime? [J].

Poletajew, Slawomir ;

Krajewski, Wojciech ;

Kryst, Piotr .

TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (06) :2479-2482

[49] Immunogenomic classification of hepatocellular carcinoma patients for immune check-point inhibitors therapy: cui bono? [J].

Hernaez, Ruben ;

Avila, Matias A. .

GUT, 2023, 72 (01) :7-9

[50] Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumours of lung (LCNET) [J].

Sherman, S. ;

Rotem, O. ;

Zer, A. ;

Shochat, T. ;

Dudnik, E. .

ANNALS OF ONCOLOGY, 2019, 30

← 1 2 3 4 5 →